Sean T. Bailey

Sean T. Bailey

Auto-generated profile, based on publicly available information

Sean T. Bailey

Lineberger Comprehensive Cancer Center

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2019 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
DWDane M Wolf
Dane M Wolf
MSMayuko Segawa
Mayuko Segawa
AKArun Kumar Kondadi
Arun Kumar Kondadi
RARuchika Anand
Ruchika Anand
SBSean T Bailey
Sean T Bailey
OSOrian Shirihai
Orian Shirihai
The mitochondrial membrane potential (ΔΨ m ) is the main driver of oxidative phosphorylation (OXPHOS). The inner mitochondrial membrane (IMM), consisting of cristae and inner boundary membranes (IBM), is considered to carry a uniform ΔΨ m . However, sequestration of OXPHOS components in cristae membranes necessitates a re‐examination of the equipotential representation of the IMM. We developed an approach to monitor ΔΨ m at the resolution of individual cristae. We found that the IMM was divided into segments with distinct ΔΨ m , corresponding to cristae and IBM. ΔΨ m was higher at cristae compared to IBM. Treatment with oligomycin increased, whereas FCCP decreased, ΔΨ m heterogeneity along the IMM. Impairment of cristae structure through deletion of MICOS‐complex components or Opa1 diminished this intramitochondrial heterogeneity of ΔΨ m . Lastly, we determined that different cristae within the individual mitochondrion can have disparate membrane potentials and that interventions causing acute depolarization may affect some cristae while sparing others. Altogether, our data support a new model in which cristae within the same mitochondrion behave as independent bioenergetic units, preventing the failure of specific cristae from spreading dysfunction to the rest.

14 November 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CSClaudio Scafoglio
Claudio Scafoglio
BVBrendon Villegas
Brendon Villegas
GAGihad Abdelhady
Gihad Abdelhady
SBSean T. Bailey
Sean T. Bailey
JLJie Liu
Jie Liu
DSDavid B. Shackelford
David B. Shackelford
The diagnostic definition of indeterminate lung nodules as malignant or benign poses a major challenge for clinicians. We discovered a potential marker, the sodium-dependent glucose transporter 2 (SGLT2), whose activity identified metabolically active lung premalignancy and early-stage lung adenocarcinoma (LADC). We found that SGLT2 is expressed early in lung tumorigenesis and is found specifically in premalignant lesions and well-differentiated adenocarcinomas. SGLT2 activity could be detected in vivo by positron emission tomography (PET) with the tracer methyl 4-deoxy-4-[18F] fluoro-alpha-d-glucopyranoside (Me4FDG), which specifically detects SGLT activity. Using a combination of immunohistochemistry and Me4FDG PET, we identified high expression and functional activity of SGLT2 in lung premalignancy and early-stage/low-grade LADC. Furthermore, selective targeting of SGLT2 with FDA-approved small-molecule inhibitors, the gliflozins, greatly reduced tumor growth and prolonged survival in autochthonous mouse models and patient-derived xenografts of LADC. Targeting SGLT2 in lung tumors may intercept lung cancer progression at early stages of development by pairing Me4FDG PET imaging with therapy using SGLT2 inhibitors.

16 August 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
ATAndrew S. Truong
Andrew S. Truong
MZMi Zhou
Mi Zhou
BKBhavani Krishnan
Bhavani Krishnan
TUTakanobu Utsumi
Takanobu Utsumi
UMUjjawal Manocha
Ujjawal Manocha
WKWilliam Y. Kim
William Y. Kim
Although immune-checkpoint inhibitors (ICIs) have been a remarkable advancement in bladder cancer treatment, the response rate to single-agent ICIs remains suboptimal. There has been substantial interest in the use of epigenetic agents to enhance ICI efficacy, although precisely how these agents potentiate ICI response has not been fully elucidated. We identified entinostat, a selective HDAC1/3 inhibitor, as a potent antitumor agent in our immune-competent bladder cancer mouse models (BBN963 and BBN966). We demonstrate that entinostat selectively promoted immune editing of tumor neoantigens, effectively remodeling the tumor immune microenvironment, resulting in a robust antitumor response that was cell autonomous, dependent upon antigen presentation, and associated with increased numbers of neoantigen-specific T cells. Finally, combination treatment with anti–PD-1 and entinostat led to complete responses and conferred long-term immunologic memory. Our work defines a tumor cell–autonomous mechanism of action for entinostat and a strong preclinical rationale for the combined use of entinostat and PD-1 blockade in bladder cancer.